---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000069"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:25:10.519004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech subsidiary Jeune reports 100% investigator-rated GAIS improvement in Phase 1 KB304 study

## Summary
- PEARL-2 Phase 1 trial: 100% of KB304-treated subjects achieved ≥1-point investigator GAIS improvement at 1,2,3 months vs 14-29% for placebo.
- 81.8% of KB304 subjects reported improved satisfaction on SSQ at 3 months vs 14.3% for placebo; improvements also seen in elasticity, crepiness, hydration, radiance.
- Safety consistent with prior KB301 experience: no severe or drug-related serious AEs; AEs mild-to-moderate and decreased with subsequent doses.
- Company plans to meet with FDA in H2 2025 to align on Phase 2 protocol; target Phase 2 start in H1 2026 for décolleté wrinkles.
- KB304 is first candidate to combine collagen (COL3) and elastin delivery via gene therapy to restore skin naturally.

## SEC filing metadata
- accession: 0001711279-25-000069
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/0001711279-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000069/krys-20250724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000069
- JSON: https://secwatch.observer/filing/0001711279-25-000069.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.